Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival

Nutrition and Cancer

Volumn 55, Issue 1, 2006, Pages 78-85

  Read, Jane A ^a   Choy, S T Boris ^c   Beale, Philip J ^b   Clarke, Stephen J ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; BODY WEIGHT; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DEMOGRAPHY; FEMALE; FOLLOW UP; GLASGOW COMA SCALE; HIGH RISK PATIENT; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; PATIENT GENERATED SUBJECTIVE GLOBAL ASSESSMENT; PROGNOSIS; SCORING SYSTEM; UNIVARIATE ANALYSIS;

ADULT; AGED; ALKALINE PHOSPHATASE; BODY WEIGHT; C-REACTIVE PROTEIN; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; FEMALE; HEALTH STATUS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NUTRITIONAL STATUS; ODDS RATIO; PALLIATIVE CARE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TERMINALLY ILL;

EID: 33749178081     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5501_10     Document Type: Article

References (44)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2, 533-543, 2001.
2. Nozoe T, Saeki H, and Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 182, 197-201, 2001.
3. Nozoe T, Matsumata T, Kitamura M, and Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176, 335-338, 1998.
4. Guillem P and Triboulet JP: Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 18, 146-150, 2005.
5. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, et al.: The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103, 1856-1864, 2005.
6. Nozoe T, Matsumata T, and Sugimachi K: Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol 23, 263-266, 2000.
7. McMillan DC, Graham AF, Smith J, Wotherspoon HA, Fearon KC, et al.: Interleukin-6, neutrophilia and the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol 20, 151-154, 1994.
8. McMillan DC, Wotherspoon HA, Fearon KC, Sturgeon C, Cooke TG, et al.: A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 170, 319-322, 1995.
9. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, et al.: Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 11, 1639-1643, 2005.
10. Chung YC and Chang YF: Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83, 222-226, 2003.
11. McMillan DC, Canna K, and McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90, 215-219, 2003.
12. Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, et al.: Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94, 227-230, 2006.
13. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, et al.: Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23, 6240-6248, 2005.
14. Maltoni M and Amadori D: Prognosis in advanced cancer. Hematol Oncol Clin North Am 16, 715-729, 2002.
15. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, et al.: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41, 64-69, 2001.
16. Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, et al.: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 173, 52-55, 2005.
17. Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, et al.: Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75, 2077-2082, 1995.
18. Slaviero KA, Read JA, Clarke SJ, and Rivory LP: Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutr Cancer 46, 148-157, 2003.
19. Falconer JS, Fearon KC, Plester CE, Ross JA, and Carter DC: Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219, 325-331, 1994.
20. Staal-van den Brekel AJ, Dentener MA, Schols AM, Buurman WA, and Wouters EF: Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 13, 2600-2605, 1995.
21. Omran ML and Morley JE: Assessment of protein energy malnutrition in older persons, part II. Laboratory evaluation. Nutrition 16, 131-140, 2000.
22. Forse RA and Shizgal HM: Serum albumin and nutritional status. J Parenter Enteral Nutr 4, 450-454, 1980.
23. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, et al.: A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 92, 1834-1836, 2005.
24. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, and Dunlop DJ: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90, 1704-1706, 2004.
25. Crumley AB, McMillan DC, McKernan M, McDonald AC, and Stuart RC: Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 94, 637-641, 2006.
26. Elahi MM, McMillan DC, McArdle CS, Angerson WJ, and Sattar N: Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer 48, 171-173, 2004.
27. Ottery FD: Definition of standardized nutritional assessment and interventional pathways in oncology. Nutrition 12, S15-S19, 1996.
28. Ottery FD, Kasenic S, DeBolt S, and Rogers K: NOAT 9601 Validation Study of the PG-SGA. 4th Annul Clinical Congress of the Society of Nutritional Oncology Adjuvant Therapy, 1998.
29. Ottery FD, Kasenic S, Debolt S, and Rogers K: Volunteer network accrues >1900 patients in 6 months to validate standardized nutritional triage (abstract 282). Proc Am Soc Clin Oncol 17, 73a, 1998.
30. Bauer J, Capra S, and Ferguson M: Use of the scored patient-generated subjective global assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr 56, 779-785, 2002.
31. Grutsch J, Gupta C, Lammersfeld A, Vashi P, and Lis G: The importance of ongoing nutritional assessment in advanced colorectal cancer (abstract 3691). Proc Am Soc Clin Oncol 22, 292a, 2004.
32. O'Gorman P, McMillan DC, and McArdle CS: Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 37, 36-40, 2000.
33. Woodward M: Epidemiology: Study Design and Data Analysis (2nd ed). New York: Chapman & Hall, 2005.
34. WHO: Obesity, Preventing and Managing the Global Epidemic, 1998. http://www.iuns.org/features/obesity/obesity.htm
35. Gupta D, Lammersfeld CA, Vashi PG, Burrows J, Lis CG, et al.: Prognostic significance of subjective global assessment (SGA) in advanced colorectal cancer. Eur J Clin Nutr 59, 35-40, 2005.
36. Persson C, Sjoden PO, and Glimelius B: The Swedish version of the patient-generated subjective global assessment of nutritional status: gastrointestinal vs urological cancers. Clin Nutr 18, 71-77, 1999.
37. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, et al.: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52, 3317-3322, 1992.
38. Ramsey S and Aitchison M: Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 174, 2422-2423, 2005.
39. Rivory LP, Slaviero KA, and Clarke SJ: Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87, 277-280, 2002.
40. Mahmoud FA and Rivera NI: The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 4, 250-255, 2002.
41. Barber MD, Ross JA, and Fearon KC: Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer 35, 106-110, 1999.
42. Kotler DP: Cachexia. Ann Intern Med 133, 622-634, 2000.
43. Slaviero KA, Clarke SJ, McLachlan AJ, Blair EY, and Rivory LP: Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 57, 44-53, 2004.
44. Ravasco P, Monteiro-Orillo I, Vidal PM, and Camilo ME: Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 23, 1431-1438, 2005.